Biodesix (NASDAQ:BDSX) and Community Health Systems (NYSE:CYH) Head to Head Analysis

Biodesix (NASDAQ:BDSX – Get Free Report) and Community Health Systems (NYSE:CYH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Biodesix and Community Health Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biodesix -25.74% -442.34% -29.16%
Community Health Systems 0.31% -6.66% -1.24%

Earnings and Valuation

This table compares Biodesix and Community Health Systems”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biodesix $88.50 million 0.95 -$35.26 million ($2.76) -2.74
Community Health Systems $12.48 billion 0.02 $509.00 million $0.26 6.25

Community Health Systems has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Community Health Systems, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

21.0% of Biodesix shares are held by institutional investors. Comparatively, 85.0% of Community Health Systems shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 11.1% of Community Health Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Biodesix has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Community Health Systems has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Biodesix and Community Health Systems, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix 1 0 5 1 2.86
Community Health Systems 4 3 1 0 1.62

Biodesix presently has a consensus price target of $34.20, suggesting a potential upside of 352.38%. Community Health Systems has a consensus price target of $2.34, suggesting a potential upside of 44.10%. Given Biodesix’s stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Community Health Systems.

Summary

Community Health Systems beats Biodesix on 9 of the 15 factors compared between the two stocks.

About Biodesix

(Get Free Report)

Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.

About Community Health Systems

(Get Free Report)

Community Health Systems, Inc. is a U.S. healthcare company that, through its subsidiaries, owns, leases and operates general acute care hospitals and related healthcare facilities. Its hospitals serve local communities, with a focus on markets outside major urban centers. The company’s facilities provide a range of services, including emergency care, inpatient and outpatient treatment, surgery, diagnostic imaging and other clinical services. Related outpatient facilities extend access to care beyond the hospital setting.

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.